Back to Search Start Over

Janssen's Tremfya approved for active psoriatic arthritis

Source :
Legal Monitor Worldwide. November 27, 2020
Publication Year :
2020

Abstract

The European Commission has approved Janssens Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA). The decision allows doctors to prescribe the drug for adults with active psoriatic [...]

Subjects

Subjects :
Guselkumab
Psoriatic arthritis -- Care and treatment
Drug approval
Antiarthritic agents
Business, international
Law
Tremfya (Medication)

Details

Language :
English
Database :
Gale General OneFile
Journal :
Legal Monitor Worldwide
Publication Type :
News
Accession number :
edsgcl.642949494

Tools

Authors Abstract Subjects Details